Latest Insider Transactions at Monopar Therapeutics (MNPR)
This section provides a real-time view of insider transactions for Monopar Therapeutics (MNPR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Monopar Therapeutics to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Monopar Therapeutics's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 30
2021
|
Arthur J Klausner Director |
BUY
Exercise of conversion of derivative security
|
Direct |
752
+8.8%
|
-
|
|
Jun 30
2021
|
Michael J Brown Director |
BUY
Exercise of conversion of derivative security
|
Direct |
752
+0.35%
|
-
|
|
Jun 30
2021
|
Raymond Anderson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
752
+16.55%
|
-
|
|
Jun 30
2021
|
Christopher M Starr Director |
BUY
Exercise of conversion of derivative security
|
Direct |
752
+21.22%
|
-
|
|
Mar 31
2021
|
Raymond Anderson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
751
+19.81%
|
-
|
|
Mar 31
2021
|
Michael J Brown Director |
BUY
Exercise of conversion of derivative security
|
Direct |
751
+0.35%
|
-
|
|
Mar 31
2021
|
Arthur J Klausner Director |
BUY
Exercise of conversion of derivative security
|
Direct |
751
+9.64%
|
-
|
|
Mar 31
2021
|
Christopher M Starr Director |
BUY
Exercise of conversion of derivative security
|
Direct |
751
+26.91%
|
-
|
|
Feb 11
2021
|
Tactic Pharma LLC |
SELL
Open market or private sale
|
Direct |
125,000
-10.54%
|
$1,875,000
$15.17 P/Share
|
|
Jan 01
2021
|
Andrew Paul Mazar Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
671
-4.21%
|
$4,026
$6.12 P/Share
|
|
Jan 01
2021
|
Andrew Paul Mazar Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,937
+10.84%
|
-
|
|
Jan 01
2021
|
Chandler Robinson Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,327
-11.23%
|
$13,962
$6.12 P/Share
|
|
Jan 01
2021
|
Chandler Robinson Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,724
+24.5%
|
-
|
|
Jan 01
2021
|
Kim R Tsuchimoto Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
504
-32.39%
|
$3,024
$6.12 P/Share
|
|
Jan 01
2021
|
Kim R Tsuchimoto Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,231
+44.17%
|
-
|
|
Dec 31
2020
|
Michael J Brown Director |
BUY
Exercise of conversion of derivative security
|
Direct |
322
+0.15%
|
-
|
|
Dec 31
2020
|
Raymond Anderson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
322
+12.33%
|
-
|
|
Dec 31
2020
|
Arthur J Klausner Director |
BUY
Exercise of conversion of derivative security
|
Direct |
322
+4.87%
|
-
|
|
Dec 31
2020
|
Christopher M Starr Director |
BUY
Exercise of conversion of derivative security
|
Direct |
322
+19.99%
|
-
|
|
Sep 30
2020
|
Michael J Brown Director |
BUY
Exercise of conversion of derivative security
|
Direct |
322
+0.15%
|
-
|
|
Sep 30
2020
|
Raymond Anderson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
322
+14.07%
|
-
|
|
Sep 30
2020
|
Arthur J Klausner Director |
BUY
Exercise of conversion of derivative security
|
Direct |
322
+5.12%
|
-
|
|
Sep 30
2020
|
Christopher M Starr Director |
BUY
Exercise of conversion of derivative security
|
Direct |
322
+24.98%
|
-
|